Pancar-hybal-like peptide-1 (GLP-1) receptor agonist is known for its effectiveness of managing diabetes by enhanced insulin secretion. It is currently studying its potential impact on prostate cancer (PCA). The interesting possibilities that may affect the progress of cancer have prompted researchers to explore the impact beyond diabetes management. This fascinating development comes from Dr. Mohammed Shahait, a team of Shata University and his team, which is published in the “Cancer” magazine.
GLP-1 is a kind of intestinal hemorrida hormone, which is synthesized in the brain stem, pancreas, and intestines. It plays a vital role in the blood glucose regulation after meals. In order to offset its half-life, the GLP-1 receptor agonist (GLP-1-RAS) has been developed, which proves that it is valid in the management of diabetes. However, people’s concerns about their potential connections with cancer (such as thyroid cancer) have surfaced. The evidence related to their PCA is still no conclusion, prompting the author to study the mechanism of GLP-1-RAS that may affect PCA cells.
The team has explored several channels, including PI3K/AKT pathways, which affects the transcription factor of the pancreatic duodenal intestinal Honeobox 1 (PDX1) and FORKHEAD BOX O1 (FOXO1), which is critical to cell proliferation. GLP-1 inhibits Foxo1, promotes β-cell proliferation and enhances PDX1 activity, thereby stimulating cell proliferation. It is worth noting that GLP-1-RAS has potential in the proliferation of various cancer cells including breast cancer, ovarian, pancreatic and prostate cancer.
Among PCA cells, the activation of GLP-1-R will trigger the CAMP-level coupling reaction, thereby inhibiting the outer cell-signal regulatory kinase (ERK) and Cyclin D1, which is essential for DNA replication and cell cycle process. By activating the phosphate kinase A and AMPK, GLP-1 can offset MTOR, which is the key regulator MTOR of cell activity, and increases the level of P27, P27 (a antiproar protein). This complex network provides insights on the impact of GLP-1-RA’s potential treatment in PCA.
Dr. Shahait commented: “Our discovery shows that GLP-1-RAS, especially when combined with the combination of two-metammer or radiation therapy (such as dual-dual-dual-dual-dual-ductal or radiation therapy), shows a synergy, which can significantly reduce the size of the tumor. This is PCA management. Open new ways, especially for patients with metabolic syndrome. “
Researchers emphasized that reducing inflammation through its anti-inflammatory characteristics is an important factor in cancer progress. By reducing cytokine release and macrophage infiltration, GLP-1-RAS has inhibited the chronic inflammation process related to insulin resistance and cancer development.
In addition, the role of metabolic syndrome in PCA is studied. Metabolic syndrome is characterized by insulin resistance and high insulinmia, and has a higher incidence of ending with PCA and poor patients. GLP-Ras is known for anti-diabetes. It can reduce this risk by improving metabolic health and inhibiting cancer cell proliferation.
In vitro research shows that GLP-1-Ras, such as EX-4, significantly reduces the volume of PCA cells and enhances the effects of radiation therapy and Dorcio. This is a chemotherapy drug. The combination of EX-4 and radiation therapy shows a significant decrease in the size of the tumor, which is due to their dual effects on the stagnation and apoptosis of the cell cycle.
However, the clinical significance of these discoveries is still under research. Although GLP-1-Ras shows hope in preclinical studies, comprehensive clinical trials must be performed to determine its effectiveness and safety in PCA patients. Future research should focus on special trials to evaluate the role of GLP-1-RA in PCA management, including the potential and auxiliary therapy of the treatment at various PCA stages.
This study emphasizes the importance of exploring the new treatment pathway of PCA, especially for the importance of metabolic syndrome and diabetic patients. Just as Dr. Shahait and his colleagues concluded: “Understanding the complex relationship between GLP-RAS and PCA may lead to innovative treatment methods, thereby improving the patient’s results and quality of life.”
Journal reference
Alhajahjeh, A., Al-Faouri, R., Bahmad, HF, Bader, T. (2024). From diabetes to oncology: the dual effects of pancreatic high-glucose-1 (GLP-1) receptor agonist in prostate cancer. Cancer, 16*(1538). Doi: https: //doi.org/10.3390/cancers16081538
About the author
Dr. Mohammed Shahait He is a urological doctor who is famous for his professional knowledge and pioneering technology in the Middle East. He graduated from Jordan University of Science and Technology, and his unremitting pursuit of excellence has allowed him to receive senior training of famous institutions. He completed a resident at the Medical Center of the University of Beirut, and then obtained a professional scholarship at the robotic urology department of the Pittsburgh Medical Center and the University of Pennsylvania. Dr. Shahat played an important role in introducing pioneering medical procedures to Jordan, including the first leather kidney frozen therapy and robotic radical prostate removal. At present, he has unparalleled professional knowledge in Dubai to provide patients with patients.
In addition to his clinical honor, Dr. Shahait has been confirmed by major research on promoting the field. He obtained a large number of donations for his pioneering research, especially after prostate slicing and the bladder cancer genome landscape of the Jordanian population. Dr. Shahait’s academics can be further reflected in his editing roles in various respected urological journals.
